SRGN and esophageal squamous cell carcinoma: In both in-vivo and in-vitro experiments, SRGN activates the ERK pathway, stabilizes c-Myc, and up-regulates the secretion of matrix metalloproteinases to promote invasion and metastasis of esophageal squamous cell carcinoma (ESCC), and high expression of SRGN in serum of patients with ESCC is an independent prognostic biomarker of poor survival 63.